Japan’s First Stelara Biosimilar to Skip November Listing on Risk of Import Delays: Fuji Pharma

Syuhei Morita, Executive Corporate Officer, General Manager, Corporate Planning Department, Corporate Strategy Division (left) and Satoshi Suzuki, Director, Executive Vice President, General Manager, Corporate Strategy Division, Fuji Pharma Fuji Pharma will not be adding its biosimilar version of Stelara (ustekinumab)...read more